Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

By sjmartinez • April 23, 2024

Egeberg A, Hawkes JE, Somani N, Burge R, See K, Gallo G, McKean-Matthews M, Gooderham M, Han G, Armstrong A. Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60. Dermatol Ther (Heidelb). 2024 Apr 22. doi: 10.1007/s13555-024-01147-7. Epub ahead of print. PMID: 38647975.

Tags: Clinical outcomes, Dermatology, ixekizumab, long-term, patient-reported outcomes, psoriasis, Publications, Quality of Life, Scalp clearance

Diagnosis and management of anti-p200 pemphigoid: Perspectives of international dermatologists with expertise in immunobullous diseases

Kasperkiewicz M, Xu J, Thapa M, Culton DA, Curman P, Hashimoto T, Meijer JM, Patsatsi A, Tomayko MM, Lehman JS, Schmidt E. Diagnosis and management[...]

Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis

Armstrong AW, Ameen A, Ferrucci S, Pereyra-Rodríguez JJ, Cork MJ, Rubin C, Jarell A, Narcisi A, Becherel PA, Beecker J, Festini T, Vittrup I, Vinther[...]

Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review

Armstrong AW, Strober BE, Liu CM, Cather JC, Merola JF, Lebwohl MG. Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a[...]